Orchestra BioMed Holdings, Inc. Research and Development Expense
Orchestra BioMed Holdings, Inc. (OBIO) reported Research and Development Expense of $16.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. research and development expense for the quarter ending 2026-06-30 was $16.59M, a 19.76% increase year-over-year.
- Orchestra BioMed Holdings, Inc. research and development expense for the quarter ending 2026-03-31 was $15.78M, a 17.05% increase year-over-year.
- Orchestra BioMed Holdings, Inc. research and development expense for the quarter ending 2025-12-31 was $16.82M, a 53.34% increase year-over-year.
- Orchestra BioMed Holdings, Inc. research and development expense for the quarter ending 2025-09-30 was $14.03M, a 20.97% increase year-over-year.
- Orchestra BioMed Holdings, Inc. research and development expense for fiscal 2025 was $58.19M, a 35.93% increase from fiscal 2024.
- Orchestra BioMed Holdings, Inc. research and development expense for fiscal 2024 was $42.80M, a 26.56% increase from fiscal 2023.
- Orchestra BioMed Holdings, Inc. research and development expense for fiscal 2023 was $33.82M, a 54.12% increase from fiscal 2022.
- Orchestra BioMed Holdings, Inc. research and development expense for fiscal 2022 was $21.95M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.59M 10-Q · filed 2026-08-10 | $32.37M 10-Q · filed 2026-08-10 | $49.19M derived: sum of 3 quarters · filed 2026-08-10 | $63.22M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $15.78M 10-Q · filed 2026-05-12 | $32.60M derived: sum of 2 quarters · filed 2026-05-12 | $46.63M derived: sum of 3 quarters · filed 2026-05-12 | $60.48M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $16.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $30.85M derived: sum of 2 quarters · filed 2026-03-12 | $44.70M derived: sum of 3 quarters · filed 2026-08-10 | $58.19M 10-K · filed 2026-03-12 |
| 2025-09-30 | $14.03M 10-Q · filed 2025-11-10 | $27.88M derived: sum of 2 quarters · filed 2026-08-10 | $41.36M 10-Q · filed 2025-11-10 | $52.33M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $13.85M 10-Q · filed 2026-08-10 | $27.34M 10-Q · filed 2026-08-10 | $38.31M derived: sum of 3 quarters · filed 2026-08-10 | $49.90M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $13.48M 10-Q · filed 2026-05-12 | $24.45M derived: sum of 2 quarters · filed 2026-05-12 | $36.05M derived: sum of 3 quarters · filed 2026-05-12 | $47.17M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $22.57M derived: sum of 2 quarters · filed 2026-03-12 | $33.69M derived: sum of 3 quarters · filed 2026-03-12 | $42.80M 10-K · filed 2026-03-12 |
| 2024-09-30 | $11.60M 10-Q · filed 2025-11-10 | $22.72M derived: sum of 2 quarters · filed 2025-11-10 | $31.83M 10-Q · filed 2025-11-10 | $40.34M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $11.13M 10-Q · filed 2025-08-12 | $20.24M 10-Q · filed 2025-08-12 | $28.75M derived: sum of 3 quarters · filed 2025-08-12 | $37.31M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $9.11M 10-Q · filed 2025-05-12 | $17.62M derived: sum of 2 quarters · filed 2025-05-12 | $26.18M derived: sum of 3 quarters · filed 2025-05-12 | $34.68M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $17.07M derived: sum of 2 quarters · filed 2025-03-31 | $25.57M derived: sum of 3 quarters · filed 2025-03-31 | $33.82M 10-K · filed 2025-03-31 |
| 2023-09-30 | $8.56M 10-Q · filed 2024-11-12 | $17.06M derived: sum of 2 quarters · filed 2024-11-12 | $25.31M 10-Q · filed 2024-11-12 | $32.85M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $8.50M 10-Q · filed 2024-08-12 | $16.75M 10-Q · filed 2024-08-12 | $24.30M derived: sum of 3 quarters · filed 2024-08-12 | $30.20M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $8.25M 10-Q · filed 2024-05-13 | $15.80M derived: sum of 2 quarters · filed 2024-05-13 | $21.70M derived: sum of 3 quarters · filed 2024-05-13 | $26.73M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $13.44M derived: sum of 2 quarters · filed 2024-03-27 | $18.47M derived: sum of 3 quarters · filed 2024-03-27 | $21.95M 10-K · filed 2024-03-27 |
| 2022-09-30 | $5.90M 10-Q · filed 2023-11-13 | $10.93M derived: sum of 2 quarters · filed 2023-11-13 | $14.40M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $5.03M 10-Q · filed 2023-08-10 | $8.50M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $3.47M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |